Skip to content
Screener

InMed Pharmaceuticals INM Q1 2026 earnings

Reported May 6, 2026 · Before market open

Revenue$1.3MMiss by $658.6M
EPS-$0.69Beat by $93.75
Revenue estimate$659.8M
EPS estimate-$94.44

Next report

Sep 23, 2026 (In 5 days)
Revenue estimate$2.1B
EPS estimate-$94.44

Versus estimates

Revenue

Q1 2026$1.3MMiss by $658.6M
Q4 2025$1.1MQ3 2025$1.1MQ2 2025$1.8MQ1 2025$1.8MQ4 2024$772.5M

Diluted EPS

Q1 2026-$0.69Beat by $93.75
Q4 2025-$0.51Q3 2025-$0.44Q2 2025-$3.80Q1 2025-$1.94Q4 2024-$3.64

FAQ

When did InMed Pharmaceuticals report Q1 2026 earnings?
InMed Pharmaceuticals (INM) reported Q1 2026 earnings on May 6, 2026 before market open.
What were InMed Pharmaceuticals's Q1 2026 revenue and EPS?
InMed Pharmaceuticals reported revenue of $1.3M and eps of $-0.69 for Q1 2026.
Did InMed Pharmaceuticals beat estimates in Q1 2026?
Revenue missed the consensus estimate of $659.8M by $658.6M. EPS beat the consensus estimate of $-94.44 by $93.75.
How did InMed Pharmaceuticals's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 29.8% from $1.8M a year earlier and eps grew 64.4% from $-1.94.
Where can I find InMed Pharmaceuticals's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001062993-26-002371) and the 10-Q periodic report (0001213900-26-052920) directly on SEC EDGAR. The filing index links above go to sec.gov.